Data Science Analyst - Equity Research, Healthcare Team
About the job
- At least 3-5 years of experience in data science, alternative data, investment research, healthcare analytics, or a related analytical role.
- Prior experience working with investment teams, research teams, or senior business stakeholders.
- Strong Python and SQL skills.
- Comfort with artificial intelligence, large language model tooling, and agentic workflows, with the ability to apply them to streamline research and support idea generation.
- Experience working with large, messy, real-world datasets.
- Hands-on experience with alternative datasets, including sourcing and evaluating new or emerging data.
- Ability to evaluate dataset quality, bias, representativeness, and signal robustness.
- Investment acumen and curiosity about markets, companies, and how data translates into an investment thesis.
- Ability to translate ambiguous investment or business questions into concrete analyses.
- Ability to present nuanced findings to senior stakeholders.
- High judgment and comfort operating independently in ambiguous environments.
- Work as an integral part of the Healthcare team, partnering directly with Global Industry Analysts and Portfolio Managers.
- Translate broad investment questions into testable data science workflows and analytical outputs.
- Apply artificial intelligence and agentic tools to streamline research workflows and contribute to investment idea generation.
- Communicate results clearly, including limitations, confidence levels, and interpretation risk.
- Serve as an experienced data science resource across the Healthcare team's coverage areas.
- Rapidly get up to speed on new companies, sub-sectors, datasets, and business models as needed.
- Assess and sequence incoming requests based on expected investment impact, feasibility, and repeatability.
- Develop differentiated signals and analytical frameworks from alternative and structured datasets relevant to healthcare investing.
- Evaluate dataset quality, coverage, bias, and signal durability.
- Build repeatable tools, screens, and research outputs for companies and themes within the sector.
- Partner with Data Engineering to productionize high-value signals where appropriate.
About the company
Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
$66.1B
Headquarters
Boston, Massachusetts
Founded
1933
Get referred to Wellington Management
See people who can refer or advise you
Simplify's Take
What believers are saying
- Hartford Funds acquisition closes in first quarter 2027, adding wealth distribution.
- The new Wellington-Vanguard-Blackstone solutions expand access to public-private portfolios.
- Wellington’s venture, biotech, climate, and CLO launches broaden fee-bearing alternatives.
What critics are saying
- Hartford Funds integration carries execution risk until regulators approve the Q1 2027 close.
- Steve Klar’s retirement in June 2026 exposes client-platform succession risk.
- Passive giants and private-credit rivals compress Wellington’s fees and threaten AUM growth.
What makes Wellington Management unique
- Wellington blends public and private markets through alliances with Vanguard and Blackstone.
- Its $1.35 trillion platform spans 60 countries and over 2,500 institutional clients.
- Matt Witheiler’s Forbes Midas List streak validates Wellington’s late-stage growth investing credibility.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Comprehensive health coverage
Work-life balance
Financial future
Development
Company News
We just closed an employee tender offer which values ElevenLabs at $22BN, up 2x from our Series D in February. The tender was led by Wellington and T. Rowe Price, and the growth is driven by demand from enterprises to deploy ElevenAgents across sales, support, and operations. In 2022, we raised our first round at a $9 million valuation, which we announced alongside Eleven v1, our first Text to Speech model, and the first model to generate human-level speech. Four years later, as we reach our new valuation, we just released two new state-of-the-art Text to Speech models. Eleven v4 and v4 Turbo are our fastest and most emotive models yet, and are leading independent benchmarks. Alongside models, we have built a full interaction platform for AI. It allows organizations to deploy conversational agents, connected to their knowledge and systems, that interact naturally in any industry, geography, or context. This shift is driving much of our growth, with enterprise now accounting for 55% of our revenue, as businesses adopt ElevenAgents to support their customers and employees. Our technology is now used in daily operations at five of the world’s ten largest tech companies, five of the ten largest insurers, and four of the ten largest telecoms. The round was co-led by Wellington Management and T. Rowe Price, along with participation from Goldman Sachs, GIC, Ontario Teachers' Pension Plan, EQT Group, Sapphire Ventures, and BDT & MSD Partners. And grateful for ongoing support from existing investors including Andreessen Horowitz, Alkeon Capital, The D. E. Shaw Group, Disruptive, Evantic Capital, ICONIQ, and Lightspeed. Most of all, this round is for the team that built the last four years. We're just getting started! | 89 comments on LinkedIn
Immix Biopharma has priced an underwritten public offering of 11,363,637 shares of common stock at $11.00 per share, expecting gross proceeds of $125 million before deducting underwriting discounts and expenses. The offering is expected to close on or about 30 September 2026. The company intends to use the net proceeds to fund development of NXC-201, working capital, and general corporate purposes. NXC-201 is a CAR-T cell therapy being evaluated for relapsed/refractory AL Amyloidosis and has received Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy designation from the US FDA. J.P. Morgan is acting as sole book-running manager. The offering included participation from institutional investors including Eventide Asset Management, Janus Henderson Investors, Ridgeback Capital Investments, and Wellington Management.
Temporal has raised $550 million in Series E funding at a $12.55 billion valuation, led by Lightspeed Venture Partners. Co-leads include Wellington Management, Growth Equity at Goldman Sachs Alternatives, and Tiger Global. The open-source platform, which powers AI applications, has seen significant growth in 2026. Its annualised revenue run rate recently surpassed $250 million, growing more than 200% year-over-year. Net dollar retention has exceeded 200% since February. Temporal Cloud processed 1.9 trillion actions in August, up more than 350% year-over-year. Open-source installs surpassed 43 million in August, up 134% since January 2026. The company now has more than 4,300 paying customers, including OpenAI, Snap, NVIDIA, Netflix, and JPMorgan Chase. Temporal provides infrastructure for reliable execution of critical applications, from payments to autonomous AI agents.
Saudi fintech Tabby has raised $233 million in a Series F round led by Blue Pool Capital, valuing the company at $6.5 billion. The valuation nearly doubles the $3.3 billion from its February 2025 Series E. Tabby is expanding beyond buy now, pay later into consumer lending, SME finance and everyday money management. The company secured consumer and SME finance licences from SAMA in Saudi Arabia and a Stored Value Facilities licence from the UAE central bank. Tabby processes over $18 billion in annualised transaction volume across 25 million users and 70,000 business partners. The company has been profitable since 2023. Its Saudi subsidiary generated $378 million in revenue and $55 million in net profit in 2025, up 42% and 82% respectively. The transaction remains subject to regulatory approvals.
AI is raising the bar for reliability. See why Temporal's $550M Series E, backed by Lightspeed and others, is built to meet that demand.